![](https://news.europawire.eu/wp-content/uploads/2014/08/Boehringer-Ingelheim.gif)
Collaboration and licensing agreement focused on investigating up to three targets and has a potential transactional value of up to EUR 307 million, excluding royalties Expands Boehringer Ingelheim’s comprehensive R&D programme in non-alcoholic steatohepatitis (NASH) and fibrotic liver disease with … Read the full press release